US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform

Cogstate lifts profit and doubles dividend as clinical trials revenue surges

This Healthcare Stock Could Jump Nearly 40%

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

PDS Biotech Reports Second Quarter 2026 Financial Results

CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial

From petri dish to patient:biotech’s formidable obstacle course

The West Australian

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy

Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/NVIB/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.337,"aum":2460334.39,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","PPCB","IDNA","MEDX","BK4139","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443063","title":"Cogstate posts record FY26 results and deepens AI-enabled CNS trial platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443063","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660443063?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:49","pubTimestamp":1787006950,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has shared an update. Cogstate Ltd is a science-led clinical trial endpoint specialist focused on central nervous system...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-posts-record-fy26-results-and-deepens-ai-enabled-cns-trial-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QTOC","MEDX","AIPO","GDOC","ARTY","VTHR","CHAT","CNS","NVIB","IDNA","HYLG","BK4135","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660306364","title":"Cogstate lifts profit and doubles dividend as clinical trials revenue surges","url":"https://stock-news.laohu8.com/highlight/detail?id=2660306364","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660306364?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:48","pubTimestamp":1787006906,"startTime":"0","endTime":"0","summary":"Cogstate Ltd ( ($AU:CGS) ) has provided an announcement. Cogstate Ltd, a provider of digital cognitive assessment solutions for global clinical tri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cogstate-lifts-profit-and-doubles-dividend-as-clinical-trials-revenue-surges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIG","BMED","GDOC","IDNA","MEDX","NVIB","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659983127","title":"This Healthcare Stock Could Jump Nearly 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659983127","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659983127?lang=en_us&edition=fundamental","pubTime":"2026-08-15 09:30","pubTimestamp":1786757400,"startTime":"0","endTime":"0","summary":"Medpace has carved out a niche helping smaller biotech companies navigate the complicated regulatory process. By Todd ChankoBy the time any of us stop by our local pharmacy to pick up a medication, th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU0130518102.USD","LU1261432733.SGD","BK4137","LU1791710582.SGD","LABU","IQV","LU0130517989.USD","LU2065171311.SGD","LU0130102774.USD","LU0477156797.USD","LU0477156953.USD","LU0528227936.USD","LU0882574055.USD","LU1989764748.USD","LU2065170008.USD","LU1791710400.SGD","LU2065171402.SGD","EKG","LU0130103400.USD","LU0198837287.USD","LU0980610538.SGD","BK4588","BK4121","FTRE","BK4581","LU0029874061.USD","BK4530","LU0648000940.SGD","XBI","LU0128526141.USD","LU1201861165.SGD","LU1201861249.SGD","NVIB","HCSG","HEAL","LU0648001328.SGD","XLV","MEDP","LU1989764664.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126775","title":"Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126775","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126775?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737900,"startTime":"0","endTime":"0","summary":"EB-003 Development Highlights:--  Continued advancing IND-enabling studies supporting the planned. submission of an Investigational New Drug  application for EB-003. --  Reported preclinical data demonstrating that EB-003 consistently. exhibited a non-hallucinogenic profile in a highly sensitive. --  Announced promising results from preclinical in vitro experiments. indicating no photoreactive potential for EB-003, further derisking its. continued development as a potential treatment of neuropsychiatric. --  Initiated genotoxicity studies to evaluate the potential for EB-003 to. interact with DNA and cause genetic mutations, a critical measure of. --  Secured U.S. Patent No. 12,605,361 pertaining to the Company's EVM301. Series of molecules being developed as potential treatments for mental","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MEDX","BK4099","BK4588","NVIB","IND","TM","BK4604","GDOC","03160","IDNA","ENVB","BK4007","HYLG","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141595","title":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141595?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP companion diagnostic i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345276/0/en/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","ALLR","CDMO","BK4535","LENZ","BK4007","BK4023","BK4503","BK4539","PLTM","BK4139","CLIA","API","GDOC","IDNA","NVIB","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","BK4139","BK4022","HYLG","IDNA","SLE","NVIB","MEDX","BMED","LABU","GDOC","CAR","FATE","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145865","title":"Press Release: Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145865","media":"Dow Jones","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145865?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"US$9.5 million as of June 30, 2026, increased from US$4.1 million as of. -- Cash and cash equivalents nearly doubled to US$3.65 million, up from. -- Total shareholders' equity increased to US$6.09 million, up approximately. 19% from US$5.10 million at December 31, 2025, reflecting a strengthened. -- Working capital improved significantly to approximately US$1.66 million. as of June 30, 2026, up from approximately US$0.42 million at December. 31, 2025, indicating strengthened short-term liquidity and full coverage. -- Quick ratio of 1.19 as of June 30, 2026, compared to 1.06 as of December. divided by current liabilities), confirming robust liquidity even on a. December 31, 2025. Importantly, approximately 47% of current liabilities,items, reflecting the Company's strong balance sheet management.Reduced Cash Burn and Cost Discipline-- Total operating expenses decreased by 53% in the second quarter of 2026. compared to the same period in 2025, to US$2.29 million from US$4.85. -- General ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LABU","LU2089283258.USD","LU0314104364.USD","BK4127","REZ","BK4585","EQR","LU2133065610.SGD","LU0912757837.SGD","BK4581","BK4551","LU0006306889.USD","LU2264538146.SGD","BK4099","NVIB","QNTM","TM","BK4596","IE00B775SV38.USD","LU0210528500.USD","LU1244550577.SGD","LU1988902786.USD","LU2023251221.USD","LU1989772923.USD","KBWB","LU0098860793.USD","LU0106261372.USD","LU1548497426.USD","VMRK","LU0234570918.USD","LU1244550494.USD","LU1732799900.SGD","LU0267386448.USD","LCDL","LU0158827948.USD","IAI","LCID","03160","LU1791710400.SGD","LU2357305700.SGD","LU1244550221.USD","LU1791710582.SGD","BK4516","LCIZ","LU0053666078.USD","LU0106831901.USD","LU0390134368.USD","LU1732800096.USD","LU2111349929.HKD","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","IND","LU2065732104.USD","IDNA","BK4139","NVIB","BMED","MSLE","MEDX","GDOC","BK4097","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659627661","title":"CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659627661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659627661?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344920/0/en/camp4-reports-second-quarter-2026-financial-results-and-corporate-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","HYLG","MEDX","IDNA","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","IND","BK4548","BK4232","BK4568","BK4139","BK4022","BK4551","BNTX","R","BK4539","IDNA","HYLG","MEDX","NVIB","BK4585","IVVD","BK4588","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYNB","CR","CRBU","HYLG","BK4195","BK4585","BK4161","BK4539","LFSC","BK4022","GDOC","PFS","BK4230","ORR","BK4588","CNCR","FBT","IBB","NVIB","IBBQ","TBXU","CAR","GNOM","BK4139","IDNA","MEDX","LD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PDS","BK4211","GDOC","XBI","BK4585","NVIB","BK4581","HYLG","PFS","BK4092","BK4588","IDNA","MEDX","ORR","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659613658","title":"CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613658","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659613658?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:12","pubTimestamp":1786601532,"startTime":"0","endTime":"0","summary":"Amur Minerals ( ($GB:CRTX) ) has shared an announcement. CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LENZ","MEDX","HYLG","NVIB","IDNA","GDOC","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659131647","title":"From petri dish to patient:biotech’s formidable obstacle course","url":"https://stock-news.laohu8.com/highlight/detail?id=2659131647","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659131647?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:12","pubTimestamp":1786576331,"startTime":"0","endTime":"0","summary":"A biotech breakthrough can be worth billions – if it survives the journey. Bulls N’ Bears follows the trek from a promising discovery through to a product doctors can actually use.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22720423/37f3ab3f7c773a9a699efc346c96f6d2e782abe6.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/from-petri-dish-to-patientbiotechs-formidable-obstacle-course-c-22720423","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["XBIX","EES","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TECB","BMED","LFSC","FRTY","LENZ","IEIH","BK4007","BBP","MRNX","BK4588","BK4139","BK4539","MEDI","IDNA","PINK","LABU","IYH","MRNY","BK4585","SYNB","GDOC","IBB","RSPH","NVIB","PSCH","XLVX","TBXU","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","IND","MEDX","GDOC","BK4081","NVIB","BK4139","LGVN","DMC","EMA","BK4232","BK4132","AD","BK4189","IDNA","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658700929","title":"NeuroThera Labs Wins Japanese Patent for Next-Generation Pain and Fever Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658700929","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658700929?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:08","pubTimestamp":1786540125,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs Inc., a clinical-stage biotech and majority-owned subsidiary of SciSparc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-wins-japanese-patent-for-next-generation-pain-and-fever-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","BBC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972189","title":"Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972189?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"double-blind, placebo-controlled global trial evaluating two doses of. AP01 dosed twice daily in patients with progressive pulmonary fibrosis. . This 52-week trial is designed to assess safety and efficacy of. AP01, with a primary endpoint of change in lung function measured by. forced vital capacity . The study overenrolled beyond its target. enrollment of 375, with a total of 398 patients randomized into three. treatment cohorts. Topline data are anticipated in the second half of. -- In September 2026, the Company plans to present two abstracts at the ERS. Congress in Barcelona, Spain. The first poster will highlight data. modeling effective AP01 distribution throughout the target tissue in both. healthy and idiopathic pulmonary fibrosis  lungs. The second poster. will describe the integration of patient perspectives into clinical trial. design. Detailed poster session information will be provided in advance","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NVIB","MEDX","FVC","IDNA","GDOC","AVLN","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658089139","title":"Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658089139","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658089139?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Socie","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343572/0/en/avalyn-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","FVC","NVIB","IDNA","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":5,"totalSize":170,"code":"91000000","status":"200"}]}}